Use of selective substrates and inhibitors to rapidly characterise batches of cryopreserved primary human hepatocytes for assessment of active uptake liability in drug discovery and development

References

• Bi YA, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildhede A, Costales C, Rodrigues AD, Varma MVS. 2018. Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug. J Pharmacol Exp Ther. 364(3):390–398.
   PubMed Web of Science ®Google Scholar
• Burckhardt G, Burckhardt BC. 2011. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol. (201):29–104.
   PubMedGoogle Scholar
• Cerny MA. 2016. Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 44(8):1246–1252.
   PubMed Web of Science ®Google Scholar
• EMA. 2012. Guideline on the investigation of drug interactions. Committee for human medicinal products (CHMP) of the European Medicines Agency (EMA). Doc. Ref. CPMP/EWP/560/95/Rev. 1 corr. 2**. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.
   Google Scholar
• FDA. 2020. In vitro drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. [cited 2020 January]. Available from: https://www.fda.gov/media/134582/download.
   Google Scholar
• Guo C, Brouwer KR, Stewart PW, Mosley C, Brouwer KLR. 2019. Probe cocktail to assess transporter function in sandwich-cultured human hepatocytes. J Pharm Pharm Sci. 22(1):567–575.
   PubMedGoogle Scholar
• Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 1609(1):1–18.
   PubMed Web of Science ®Google Scholar
• Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R. 2010. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 88(6):682–691.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. 2006. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 34(7):1109–1115.
   PubMed Web of Science ®Google Scholar
• Iwai M, Minematsu T, Narikawa S, Usui T, Kamimura H. 2009. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-napht ho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 37(9):1856–1863.
   PubMed Web of Science ®Google Scholar
• Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, et al. 2012. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 40(5):1007–1017.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 308(1):2–9.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Feng B, Nguyen HT, Frederick KS, Campbell SD, Hatch HL, Bi YA, Kazolias DC, Davidson RE, Mireles RJ, et al. 2007. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab Dispos. 35(11):2111–2118.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. 2012. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 29(2):411–426.
   PubMed Web of Science ®Google Scholar
• Konig J, Cui Y, Nies AT, Keppler D. 2000. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 275(30):23161–23168.
   PubMed Web of Science ®Google Scholar
• Kozakai K, Yamada Y, Oshikata M, Kawase T, Suzuki E, Haramaki Y, Taniguchi H. 2014. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms. Drug Metab Pharmacokinet. 29(2):198–207.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. 2017. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Kumar V, Yin M, Ishida K, Salphati L, Hop C, Rowbottom C, Xiao G, Lai Y, Mathias A, Chu X, et al. 2021. Prediction of transporter-mediated rosuvastatin hepatic uptake clearance and drug interaction in humans using proteomics-informed REF approach. Drug Metab Dispos. 49(2):159–168.
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, Poller B. 2014. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 42(9):1514–1521.
   PubMed Web of Science ®Google Scholar
• Lee HH, Ho RH. 2017. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 83(6):1176–1184.
   PubMed Web of Science ®Google Scholar
• Li N, Badrinarayanan A, Li X, Roberts J, Hayashi M, Virk M, Gupta A. 2020. Comparison of in vitro to in vivo extrapolation approaches for predicting transporter-mediated hepatic uptake clearance using suspended rat hepatocytes. Drug Metab Dispos. 48(10):861–872.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, Galetin A. 2012. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 341(1):2–15.
   PubMed Web of Science ®Google Scholar
• Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H. 2010. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 38(1):1–4.
   PubMed Web of Science ®Google Scholar
• O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. 2007. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab Dispos. 35(3):381–385.
   PubMed Web of Science ®Google Scholar
• PMDA 2019. Guideline on drug interaction for drug development and appropriate provision of information Available from: https://www.pmda.go.jp/files/000228122.pdf.
   Google Scholar
• Poirier A, Lave T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C. 2008. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos. 36(12):2434–2444.
   PubMed Web of Science ®Google Scholar
• Shen H, Lai Y, Rodrigues AD. 2017. Organic anion transporter 2: an enigmatic human solute carrier. Drug Metab Dispos. 45(2):228–236.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 304(2):610–616.
   PubMed Web of Science ®Google Scholar
• Soars MG, Webborn PJ, Riley RJ. 2009. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm. 6(6):1662–1677.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, Taub ME, Sharma A, Ebner T, et al. 2018. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. Br J Clin Pharmacol. 84(9):1941–1949.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Masuo Y, Futatsugi A, Kato Y. 2020. Static model-based assessment of OATP1B1-mediated drug interactions with preincubation-dependent inhibitors based on inactivation and recovery kinetics. Drug Metab Dispos. 48(9):750–758.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Zanetti-Yabur A, Wang P, Usyk M, Burk RD, Wolkoff AW. 2020. Interindividual diversity in expression of organic anion uptake transporters in normal and cirrhotic human liver. Hepatol Commun. 4(5):739–752.
   PubMed Web of Science ®Google Scholar
• Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, et al. 2020. Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations. Clin Pharmacol Ther. 107(5):1082–1115.
   PubMed Web of Science ®Google Scholar
• Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, et al. 2019. A clinical drug-drug interaction study assessing a novel drug transporter phenotyping cocktail with adefovir, sitagliptin, metformin, pitavastatin, and digoxin. Clin Pharmacol Ther. 106(6):1398–1407.
   PubMed Web of Science ®Google Scholar
• Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM. 2017. Extended clearance classification system (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters. Clin Pharmacol Ther. 102(1):33–36.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. 2010. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 38(2):215–222.
   PubMed Web of Science ®Google Scholar
• Xu M, McCanna DJ, Sivak JG. 2015. Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells. J Pharmacol Toxicol Methods. 71(1):1–7.
   PubMedGoogle Scholar
• Yoshida K, Maeda K, Sugiyama Y. 2012. Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 91(6):1053–1064.
   PubMed Web of Science ®Google Scholar